Adrenomedullin　(ADM)　was　first　isolated　from　pheochromocytoma　tissue　as　a　novel　vasodilative　peptide　in　1993.　ADM　binds　to　two　receptors　on　plasma　membrane　which　are　comprised　of　Calcitonin　Receptor-Like　Receptor　(CRLR),　a　member　of　serpentine　receptor　superfamily,　and　Receptor　Activity　Modifying　Protein　(RAMP)　type　2　or　3.　ADM　is　known　to　have　hypotensive　activity.　Recently,　ADM　has　been　shown　to　be　an　almost　ubiquitous　peptide,　synthesized　in　many　mammalian　tissues.　ADM　has　potent　in　vivo　angiogenic　activity　and　tumor　growth　promoting　effect　in　animal　models.　Many　human　tumors　express　ADM.　However,　only　little　information　exists　regarding　the　expression　or　the　role　of　ADM　in　bone　and　its　effect　in　bone　metabolism.　It　is　still　not　clear　whether　ADM　is　involved　in　pathogenesis　and　development　of　osteosarcoma,　the　most　common　form　of　bone　tumor.　The　purpose　of　this　review　is　to　examine　the　most　salient　features　of　adrenomedullin　biology,　its　expression　in　tumors　and　its　potential　implication　in　the　treatment　of　bone　tumors.